Conference Reports for NATAP

Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) Taipei, Taiwan February 16-19, 2012 Back

Asians have Different Hepatitis B Surface Antigen (HBsAg) Kinetics than Non-Asians while Undergoing Treatment with Tenofovir Disoproxil Fumarate (TDF) or Adefovir (ADV) Followed by TDF up to 192 Weeks       Reported by Jules Levin 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) February 16-19, 2012 Taipei, Taiwan   S Fung1, E Gane2, IM Jacobson3, P Dinh4, R Ebrahimi4, LJ Yee4, EB Martins4, P Charuworn4, K Kitrinos4, G Dusheiko5, H Trinh6, S Gordon7, R Flisiak8, EJ Heathcote1 and P Marcellin9 1University of Toronto, Toronto, ON, Canada; 2Auckland City Hospital, Auckland, New Zealand; 3Weill Medical College of Cornell University, New York, NY, USA; 4Gilead Sciences, Foster City, CA, USA; 5Royal Free Hospital, London, UK; 6San Jose Gastroenterology, San Jose, CA, USA; 7Henry Ford Medical Center, Detroit, MI, USA; 8Medical University of Bialystok, Bialystok, Poland; 9Hopital Beaujon, University of Paris, Clichy, France   Introduction   · In registration studies of tenofovir disoproxil fumarate (TDF), HBsAg loss has been described in 11% of patients over 5 years 1,2 - Clinical characteristics such as ALT elevations and HBeAg loss have also been described in some patients with HBsAg loss [see Marcellin et al. Poster: PP09-042] - In these studies, HBsAg loss has not been observed in Asians · Little is known about individuals who have significant HBsAg declines in the absence of HBsAg loss · Also, it is unknown whether Asians and non-Asians have different HBsAg kinetics during treatment with TDF   Objective   · To evaluate the kinetics of HBsAg decline between Asian and non-Asian patients treated with TDF or adefovir dipivoxil (ADV) followed by TDF   Methods   · Data analyzed from two pivotal TDF studies1 - GS-US-174-0102 · HBeAg-negative patients · 375 patients enrolled - GS-US-174-0103 · HBeAg-positive patients · 266 patients enrolled   · Study design (Figure 1) - TDF or ADV for 48 weeks, followed by TDF for another 192 weeks - The present analyses are based on data through year 4